Hill October 13, 2024
Joseph Choi

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years.

Pharmacies that sold unbranded copies of those drugs are mounting a coordinated effort to reverse this decision, as another fight over the wildly popular drugs Ozempic and Wegovy looms.

Mounjaro and Zepbound are both names for the drug tirzepatide, the diabetes and obesity medication made by the multinational pharmaceutical giant Eli Lilly. It falls in the same class of drugs as Ozempic and Wegovy, all of them being GLP-1 agonists.

Tirzepatide was first approved by the Food and Drug Administration (FDA) in 2022 and has no generic versions on the market....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Related Articles:
Regulatory Hurdles and Ethical Concerns in FDA Oversight of AI/ML Medical Devices
The Current State Of Almost 950 FDA-Approved, AI-Based Medical Devices
Cytovale Secures $100M to Expand Commercialization of FDA-Cleared Sepsis Test
FDA's Promised Guidance on Pulse Oximeters Unlikely to End Decades of Racial Bias
AI explained: AI and FDA device regulation

Share This Article